Home / 2021 / February / 22

Daily Archives: February 22, 2021

Accellion Provides Update to FTA Security Incident Following Mandiant’s Preliminary Findings

Mandiant Identifies Criminal Threat Actor and Mode of Attacks

PALO ALTO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — Accellion, Inc., provider of the industry’s first enterprise content firewall, today issued a statement regarding Mandiant’s preliminary findings with regards to the previously reported cyberattacks on Accellion’s legacy FTA product.

Mandiant, a division of FireEye, Inc., has identified UNC2546 as the criminal hacker behind the cyberattacks and data theft involving Accellion’s legacy File Transfer Appliance product. Multiple Accellion FTA customers who have been attacked by UNC2546 have received extortion emails threatening to publish stolen data on the “CL0P^_- LEAKS” .onion website. Some of the published victim data appears to have been stolen using the DEWMODE web shell. Mandiant is tracking the subsequent extortion activity under a separate threat cluster, UNC2582.

Accellion strongly recommends that FTA customers migrate to kiteworks, Accellion’s enterprise content firewall platform. These exploits apply exclusively to Accellion FTA clients: neither kiteworks nor Accellion the company were subject to these attacks. Kiteworks is built on an entirely different code base, using state-of-the-art security architecture, and a segregated, secure devops process. The kiteworks platform is FedRAMP authorized for Moderate CUI, and demonstrates compliance with GDPR, HIPAA, NIST 800-171, FIPS, SOC2, ISO 27001, and other data privacy regulations and standards.

Accellion has patched all known FTA vulnerabilities exploited by the threat actors and has added new monitoring and alerting capabilities to flag anomalies associated with these attack vectors.

Accellion does not access the information that its customers transmit via FTA. Following the attack, however, Accellion has worked at many customers’ request to review their FTA logs to help understand whether and to what extent the customer might have been affected. As a result, Accellion has identified two distinct groups of affected FTA customers based on initial forensics. Out of approximately 300 total FTA clients, fewer than 100 were victims of the attack. Within this group, fewer than 25 appear to have suffered significant data theft.

Accellion continues to offer support to all affected FTA customers to mitigate the impact of the attack.

The following CVEs have since been reserved for tracking the recently patched Accellion FTA vulnerabilities:

To read Mandiant’s preliminary findings on the cyberattack on Accellion’s legacy FTA product, please visit https://www.fireeye.com/blog/threat-research/2021/02/accellion-fta-exploited-for-data-theft-and-extortion.html. Mandiant’s complete report will be made available in the coming weeks.

To learn more how Accellion helps organizations secure their third party communications, please visit Enterprise Content Firewall.

About Accellion
The Accellion enterprise content firewall prevents data breaches and compliance violations from sensitive third party communications. With Accellion, CIOs and CISOs gain complete visibility, compliance, and control over IP, PII, PHI, and other sensitive content across all third-party communication channels, including email, file sharing, mobile, enterprise apps, web portals, SFTP, and automated inter-business workflows. Accellion has protected more than 25 million end users at more than 3,000 global corporations and government agencies, including NYC Health + Hospitals; KPMG; Kaiser Permanente; AVL; American Automobile Association (AAA); Linde Gas; Tyler Technologies; and the National Institute for Standards and Technology (NIST). For more information, please visit www.accellion.com or call (650) 485-4300. Follow Accellion on LinkedInTwitterFacebook, and Accellion’s Blog.

Media Contact
Rob Dougherty
(650) 687-3163
robert.dougherty@accellion.com

Accellion and kiteworks are registered trademarks of Accellion USA LLC. in the US and other countries. All other trademarks contained herein are the property of their respective owners.

 

Global Real Estate Leader JLL Begins Transition to Altus Group’s Cloud-Enabled ARGUS Enterprise

Altus Group’s integrated cloud-based software will enable JLL’s businesses to enhance workflow capabilities with a single source of data

TORONTO, Feb. 22, 2021 (GLOBE NEWSWIRE) — Altus Group Limited (ʺAltus Groupʺ) (TSX: AIF), a leading provider of commercial real estate (“CRE”) services, software and data solutions, is pleased to announce that JLL, a global leader in commercial real estate professional services and investment management, has chosen to expand its use of ARGUS Enterprise (“AE”). Through this agreement, JLL, and its subsidiary LaSalle Investment Management, will be able to start using cloud-enabled AE and begin transitioning on-premise users to cloud-enabled AE.

As the demand for better data and reporting grows across the CRE industry, this multi-year global agreement will provide JLL access to ARGUS solutions that will assist in data management and accelerate key business processes. By using the offerings in ARGUS Cloud, including AE and ARGUS API, JLL’s real estate professionals will have access to an integrated suite of software, allowing teams across different geographies to access and collaborate on the same data, regardless of the stage in the property lifecycle or the level of reporting required. ARGUS API extends these capabilities by connecting CRE data between ARGUS solutions and a variety of their data sets, sources and applications for specialist functions of JLL.

“We are pleased to continue to work closely with a world-class leader like JLL. Their continued commitment to ARGUS Enterprise speaks to our leadership in helping clients around the world successfully manage today’s real estate industry market pressures,” said Mike Gordon, Chief Executive Officer at Altus Group. “Transitioning to cloud-enabled ARGUS Enterprise will enable JLL to deliver greater visibility, increase efficiency and drive enhanced performance.”

“We are committed to supporting tools and processes that enable JLL’s valuation, capital markets and investment management businesses to deliver more value to clients. With cloud-enabled ARGUS Enterprise, we can enhance collaboration, drive more efficient processes and bring greater transparency to our global business,” said Mark Wynne-Smith, Global Head, JLL Valuation Advisory.

Altus Group surpassed a significant 1,000 customer milestone for cloud-enabled ARGUS Enterprise at the end of December 2020, further solidifying it as the global industry standard for commercial real estate valuations, asset and investment management.

About Altus Group Limited

Altus Group Limited is a leading provider of software, data solutions and independent advisory services to the global commercial real estate industry. Our businesses, Altus Analytics and Altus Commercial Real Estate Consulting, reflect decades of experience, a range of expertise, and technology-enabled capabilities. Our solutions empower clients to analyze, gain insight and recognize value on their real estate investments. Headquartered in Canada, we have approximately 2,200 employees around the world, with operations in North America, Europe and Asia Pacific. Our clients include some of the world’s largest real estate industry participants. Altus Group pays a quarterly dividend of $0.15 per share and our shares are traded on the TSX under the symbol AIF.

For more information on Altus Group, please visit: www.altusgroup.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Altus Group Limited

Camilla Bartosiewicz
Vice President, Investor Relations
416-641-9773
camilla.bartosiewicz@altusgroup.com

Elizabeth Lambe
Senior Manager, Global Communications
416-641-9787
elizabeth.lambe@altusgroup.com

 

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico

  • PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and Mexico

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine. Novavax has previously reported positive interim efficacy results of NVX-CoV2373, its recombinant protein-based vaccine candidate, in an ongoing Phase 3 clinical trial taking place in the United Kingdom.

“The full enrollment of PREVENT-19 is another important step in building a body of evidence to demonstrate that NVX-CoV2373 will be safe and effective across diverse, representative populations,” said Gregory M. Glenn, President of Research and Development, Novavax. “We thank the thousands of volunteers and individuals, including our partners at NIH, the COVID-19 Prevention Network and trial sites in the U.S. and Mexico, who enabled rapid recruitment and enrollment in the trial, which we believe is a critical aspect to building vaccine trust and uptake across the globe.”

PREVENT-19 was planned with specific recruitment diversity and representation goals and enrolled 30,000 volunteers. Location of trial sites emphasized communities and demographic groups most impacted by the disease, including those living with co-morbid conditions that place them at higher risk of complications from COVID-19. The trial largely reached its demographic goals amid the concurrent rollout of vaccines authorized for emergency use.

The trial enrolled diverse participants as follows:

  • LatinX: 20%
  • African American: 13%
  • Native American: 6%
  • Asian American: 5%
  • Older adults (65 years and older): 13%

PREVENT-19 is a randomized, placebo-controlled, observer-blinded study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373 with Matrix-M in up to 30,000 subjects 18 years of age and older compared with placebo. Two thirds of the participants are assigned to randomly receive two intramuscular injections of the vaccine, administered 21 days apart, while one third of the trial participants receive placebo. Trial sites were also selected in locations where transmission rates were high to accelerate the accumulation of positive cases that could show efficacy.

PREVENT-19 is being conducted with support from the U.S. government partnership (formerly Operation Warp Speed), which includes the Department of Defense, the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at HHS. BARDA is also providing up to $1.75 billion under a Department of Defense agreement.

About NVX-CoV2373

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with Novavax’ patented saponin-based Matrix-M™ to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that block binding of the spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response numerically superior to that seen in human convalescent sera in Phase 1/2 clinical testing. NVX-CoV2373 is currently being evaluated in two pivotal Phase 3 trials: a trial in the U.K that demonstrated 89.3 percent overall efficacy and 95.6 percent against the original strain in a post-hoc analysis, and the PREVENT-19 trial in the U.S. and Mexico that began in December. It is also being tested in two ongoing Phase 2 studies that began in August: A Phase 2b trial in South Africa that demonstrated 50-60 percent efficacy against newly emerging escape variants, and a Phase 1/2 continuation in the U.S. and Australia.

About Matrix-M™
Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Novavax Forward Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, and Quarterly Report on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:

Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Jennifer Porcelli | 617-974-8659
jporcelli@soleburytrout.com

Media
Amy Speak | 617-420-2461
Laura Keenan | 410-419-5755
media@novavax.com

 

TigerGraph Raises $105 Million to Accelerate Graph Analytics on the Cloud

Record Funding for Graph Database Category, Led by Tiger Global, Signals the Next Wave in Analytics to Fuel Powerful Insights for Artificial Intelligence

SINGAPORE, Feb. 22, 2021 (GLOBE NEWSWIRE) — TigerGraph, provider of the leading graph analytics platform, today announced it has raised $105 million in Series C funding, the largest funding round to date within the graph database and analytics market. The round was led by Tiger Global and brings TigerGraph’s total funding raised to over $170 million. TigerGraph already has a presence in China and is opening offices in Singapore and in Indonesia.

“The Asia Pacific digital economy continues to grow, and we are seeing increased regional demand. To tap this potential and to better serve our customers in the region, we will be opening offices in Singapore and in Indonesia. TigerGraph’s initiatives in Asia will be led by Joseph (Joe) Lee, an enterprise software sales and business veteran, as Vice President, Asia Pacific and Japan. We are expanding at the speed of business and are actively hiring for key positions in Asia,” said Todd Blaschka, COO, TigerGraph.

“Our mission is to help governments, businesses and people to unlock the power of their data and drive actionable, real-time insights-driven decision-making. TigerGraph already works with the top four largest banks in Asia helping these customers across areas such as Real-time Fraud Detection, Anti-Money Laundering, Credit Risk Assessment, and Customer 360 Analysis. We also work with key telcos in the region, enabling them to analyse customer behaviour and prevent fraud,” he added.

The investment reflects TigerGraph’s growth and the massive potential as businesses continue to move to the cloud. With the transactional and analytical workloads moving to the cloud made possible by companies like Snowflake, Confluent, and Databricks, TigerGraph is quickly becoming the graph database of choice to connect, analyze and learn new insights from the data. With its distributed native graph architecture, TigerGraph helps organizations scale fast, analyze many different aspects of data to be used with each other to form new models and generate new insights. These new patterns and insights enhance a company’s analytics or machine learning capabilities and can be deployed anywhere with multi-cloud flexibility and support the data security requirements for regulatory compliance.

Over the last 12 months with the COVID-19 pandemic, companies have embraced digital transformation at a faster pace driving an urgent need to find new insights about their customers, products, services, and suppliers. Graph technology connects these domains from the relational databases, offering the opportunity to shrink development cycles for data preparation, improve data quality, identify new insights such as similarity patterns to deliver the next best action recommendation. Data-driven solutions require intelligent apps and connected data that leverage powerful graph engines to connect, analyze and learn from the data companies are storing in the cloud. These events helped TigerGraph experience massive growth, more than doubling revenues and customers over the past year. It has also continued building a very active and fast-growing developer community, receiving the highest markets in a recent analyst report — TigerGraph was named a leader for Graph Data Platforms in the analyst report.

“By 2023, graph technologies will facilitate rapid contextualization for decision making in 30 percent of organizations worldwide,” according to Gartner.¹ Mark Beyer, Distinguished VP Analyst with Gartner shared the following in a Gartner report regarding the adoption of graph technology in the enterprises, “To Graph or Not to Graph? That Is Not the Question — You Will Graph.”² Organizations of all sizes are adopting Graph-based analytics and AI by leveraging the relationships in the connected data to drive better outcomes. TigerGraph is galvanizing the graph and AI community, organizing the first open industry Graph + AI Conference featuring presentations by innovators including UnitedHealth Group, Jaguar Land Rover, Intuit, Intel, Xilinx and Accenture. TigerGraph is deeply involved and on the steering committee for the development of the Graph Query Language standard, GQL along with other database vendors such as Oracle and Neo4j, and will enthusiastically support the GQL standard immediately upon finalization.

“For over 40 years, business’s #1 data management challenge has been how to easily ask business questions across all of their data in real-time to guide their operations. The human brain connects data to derive new insights and helps us decide what to do next. TigerGraph’s mission is to power an enterprise brain with graph and AI that discovers these new insights within the enterprise data stored in the cloud and on-prem,” said Dr. Yu Xu, founder and CEO of TigerGraph. “TigerGraph is leading the paradigm shift in connecting and analyzing data via scalable and native graph technology with pre-connected entities versus the traditional way of joining large tables with rows and columns. This funding will allow us to expand our offering and bring it to many more markets, enabling more customers to realize the benefits of graph analytics and AI.”

TigerGraph’s innovation has been recognized with several recent industry awards and accolades including:

The company will use the funding for product innovation and development to better support its customers, including TigerGraph Cloud on Google Cloud Platform (available March 2021), plus further multi-region support on AWS and Azure. It is also expanding its global reach with local support in Asia and Australia/New Zealand. Meanwhile, the company will scale up with additional hiring in the Americas, EMEA, and APAC to meet increased product demand. The company is hiring in every department — apply now at https://www.tigergraph.com/join-us/.

Helpful Links

¹ Gartner Press ReleaseGartner Identifies Top 10 Data and Analytics Technology Trends for 2020, 22 June 2020

² Gartner, Graph Steps Onto the Main Stage of Data and Analytics: A Gartner Trend Insight Report, 14, December 2020

About TigerGraph

TigerGraph is a platform for advanced analytics and machine learning on connected data. Based on the industry’s first and only distributed native graph database, TigerGraph’s proven technology supports advanced analytics and machine learning applications such as fraud detection, anti-money laundering (AML), entity resolution, customer 360, recommendations, knowledge graph, cybersecurity, supply chain, IoT, and network analysis. The company is headquartered in Redwood City, California, USA. Start free with tigergraph.com/cloud.

Media Contact
Rajiv Menon
PRecious Communications for TigerGraph
rajiv@preciouscomms.com

NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy

— 1st approval of any checkpoint inhibitor in nasopharyngeal carcinoma in the world

— 2nd indication approved for Toripalimab in China

SHANGHAI, China, Feb. 22, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy. This is the first approval of immune checkpoint blockade therapy in NPC in the world and the second approved indication for toripalimab in China. In December 2018, Toripalimab obtained a conditional approval from the NMPA for the second-line treatment of unresectable or metastatic melanoma.

In April 2020, the supplemental NDA for Toripalimab in patients with recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy was accepted by the NMPA and received priority review designation from the NMPA in July 2020. The supplemental NDA is based on the POLARIS-02 study (NCT02915432), which is a multi-center, open-label, Phase II pivotal registrational clinical study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center. The study enrolled a total of 190 patients with recurrent or metastatic NPC after failure of prior systemic therapy. The POLARIS-02 study is the world’s largest clinical study for any immune checkpoint inhibitor monotherapy for the treatment of recurrent or metastatic NPC. In January 2021, the results of the POLARIS-02 study were published online in the Journal of Clinical Oncology.

The results of the POLARIS-02 study showed that Toripalimab demonstrated durable anti-tumor activity and survival benefits regardless of PD-L1 expression status with a manageable safety profile. In 92 patients with recurrent/metastatic NPC after failure of at least two lines of prior systemic chemotherapy, the objective response rate (ORR) was 23.9%; the median duration of response (mDOR) 14.9 months; and the median overall survival (mOS) 15.1 months.

“The great variability in prevalence of NPC across the globe is evident, which leads to challenges in new drug research and development on a global scale. Despite this, unmet medical needs for NPC remain globally. Our data show that NPC is clearly responsive to immunotherapy. It is notable that toripalimab lacks the usual side effects of cytotoxic therapy and is generally well tolerated by patients, showing a great potential for further development in the treatment of NPC,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “As an innovation-driven pharma who follows the ‘In China, For Global’ strategy, we focus on tumor types that are 1) highly prevalent in China; 2) responsive to immunotherapy; and 3) where there is urgent unmet need for better and safer treatments. We sincerely appreciate the contributions made by investigators and patients of the POLARIS-02 study, empowering us to obtain this critical medical evidence to advance treatment options for so many. In addition, we have also developed a R & D program for treatment of NPC, regardless of extent of prior treatment, and look forward to providing better treatment options for patients with advanced nasopharyngeal carcinoma in China and beyond.”

About Nasopharyngeal carcinoma
Nasopharyngeal carcinoma is a malignant tumor that occurs in the nasopharyngeal mucosal epithelium and is one of the most common head and neck cancers. According to the World Health Organization (WHO), the number of newly diagnosed nasopharyngeal carcinoma cases in 2020 has reached approximately 133,000 worldwide, and nearly half of the cases occurred in China.

About Toripalimab
Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing in China. More than thirty company-sponsored clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States. On 17 December 2018, Toripalimab obtained a conditional approval from the NMPA for the second-line treatment of unresectable or metastatic melanoma. Toripalimab was included in the 2019 and 2020 Guidelines of Chinese Society of Clinical Oncology (CSCO) for the Diagnosis and Treatment of Melanoma. The supplemental NDA of Toripalimab for the second-line treatment of metastatic urothelial carcinoma was accepted by the NMPA in May 2020 and received priority review designations from the NMPA in July 2020. In September 2020, Toripalimab was granted Breakthrough Therapy Designation by the US Food and Drug Administration (“FDA”) for the treatment of recurrent/metastatic nasopharyngeal carcinoma. In December 2020, Toripalimab was successfully included in the updated National Reimbursement Drug List. In February 2021, the supplemental NDA application of Toripalimab in combination with chemotherapy for the first-line treatment of patients with advanced, recurrent or metastatic nasopharyngeal carcinoma was accepted by the NMPA. Currently, Toripalimab has been granted 1 Breakthrough, 1 Fast Track, and 3 Orphan Drug Designations by the FDA for the treatment of mucosal melanoma, nasopharyngeal carcinoma, and soft tissue sarcoma.

About Junshi Biosciences                   
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 27 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 adminstered with bamlanivimab has received Emergency Use Authorization (EUA) by US FDA in Feb 2021 for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization. JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800